ArticleNuclear medicine communications2026
A nomogram predicting dysphagia risk after adjuvant iodine-131 therapy in patients with papillary thyroid carcinoma.
Article in Nuclear medicine communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo identify clinical risk factors for dysphagia after iodine-131 ( 131 I) therapy in patients with papillary thyroid carcinoma (PTC) and develop a validated risk-prediction nomogram.
methodsAdult PTC patients treated with 131 I at the Department of Nuclear Medicine, Affiliated Hospital of Xuzhou Medical University, between January 2022 and October 2024 were retrospectively reviewed. All patients underwent total or partial thyroidectomy, had satisfactory postoperative wound healing, and had histopathologically confirmed PTC. Baseline clinical data, laboratory parameters, and pretreatment salivary gland function assessed by dynamic pertechnetate single-photon emission computed tomography/computed tomography were collected. Swallowing function was evaluated before treatment and at 6-month follow-up using the MD Anderson Dysphagia Inventory; dysphagia was defined as a total score less than 50. Variables significant in univariate analysis were entered into backward stepwise multivariate logistic regression. Independent predictors were used to construct a nomogram, which was assessed by area under the curve (AUC), bootstrap calibration, and decision curve analysis.
resultsAmong 201 patients, 68 (33.8%) developed dysphagia. Higher cumulative 131 I dose, smoking history, and baseline salivary gland dysfunction were independent predictors of dysphagia. The nomogram incorporating these factors showed excellent discrimination, with an AUC of 0.913, good calibration with a bootstrap mean absolute error of 0.013, and favorable clinical net benefit.
conclusionHigher 131 I dose, smoking history, and pre-existing salivary gland dysfunction independently predict dysphagia after 131 I therapy in PTC patients. This nomogram may support individualized risk assessment and preventive counseling before treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.